drugset / Trial / NCT06673238

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

NCT06673238

Phase 1 Active not recruiting 95 enrolled AbbVie
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.

Timeline

Start
2024-10-29
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-722 Unknown Oral

Indications

No indication recorded.